Regenxbio Inc. (RGNX)

From the record

Regenxbio Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Regenxbio Inc.'s 10 filed years say what it did: revenue went from $5 million in fiscal 2016 to $170 million in fiscal 2025, up 49.4% a year; it rose in 5 of 9 years; the deepest fall was 84% from fiscal 2018 to fiscal 2019; net income was positive in 2 of 10 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Regenxbio Inc. lost about 189 cents for every dollar of shareholders' money. Leverage: it owed about 77 cents per dollar of assets, and net share issuance: its share count grew 4.2% over the year (the filed statements).

From the record

Regenxbio Inc.'s standing among 102 graded names in its industry family: revenue of $170 million in fiscal 2025 ranks in the top 21% by size; a net margin of -113.8% ranks in the top 38%; revenue growth of 14.8% a year over the last 3 filed years ranks in the top 40% (its annual reports).

From the record

Regenxbio Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Simpson, Curran (Chief Executive Officer, as filed), filing under that title since 2024-07-03, 2.4 years (bottom 30% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 8.5 years (top 6%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Regenxbio Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $34 million against no long-term debt tagged leaves 7.6% of its assets as net cash, bottom 15% of its family; cash from operations less capital spending is -74.1% of revenue (top 35%); research spending of 133.9% of revenue (bottom 46%) (its annual report).

From the record

Regenxbio Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 14.8% a year over the last three filed years against 49.4% over all 10, slowing (bottom 20% of its family); the newest year grew 104.6% (top 21%); research spending grew -2% a year (bottom 39%); capital spending grew -57.2% a year (bottom 24%) (its annual reports). Regenxbio Inc. reported 2 product lines in fiscal 2025: License and Service at $156 million (92%), Service at $14 million (8%); 2 of 2 grew against the year before (its annual report).

From the record

Regenxbio Inc.'s newest year against its own record: revenue of $170 million in fiscal 2025 came in 137.9% above the $72 million its prior three years' pace pointed to (top 18% of its family); net income of $194 million against a prior three-year average of $257 million (top 41%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 40%) (its annual reports).